Curat Global LLC Invests $115,000 in Becton, Dickinson and Company (NYSE:BDX)

Curat Global LLC purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 500 shares of the medical instruments supplier’s stock, valued at approximately $115,000.

Other institutional investors have also recently bought and sold shares of the company. Hillsdale Investment Management Inc. boosted its position in Becton, Dickinson and Company by 1.7% in the 4th quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier’s stock valued at $694,000 after buying an additional 50 shares during the last quarter. Americana Partners LLC lifted its stake in shares of Becton, Dickinson and Company by 3.5% during the fourth quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier’s stock valued at $345,000 after acquiring an additional 52 shares during the period. Picton Mahoney Asset Management lifted its stake in shares of Becton, Dickinson and Company by 61.4% during the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock valued at $32,000 after acquiring an additional 54 shares during the period. REAP Financial Group LLC boosted its holdings in Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 55 shares during the last quarter. Finally, Versant Capital Management Inc increased its position in Becton, Dickinson and Company by 27.4% in the first quarter. Versant Capital Management Inc now owns 265 shares of the medical instruments supplier’s stock worth $61,000 after purchasing an additional 57 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 1.4%

BDX opened at $173.47 on Friday. The firm’s fifty day moving average is $186.95 and its two-hundred day moving average is $214.84. The firm has a market cap of $49.72 billion, a PE ratio of 28.82, a price-to-earnings-growth ratio of 1.63 and a beta of 0.25. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, beating analysts’ consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion during the quarter, compared to analysts’ expectations of $5.35 billion. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.17 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.40%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 79.39%.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. William Blair downgraded shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 1st. Raymond James lowered shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a report on Friday, May 2nd. Morgan Stanley reduced their price objective on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 6th. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Friday, May 2nd. Finally, Piper Sandler lowered Becton, Dickinson and Company from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $260.00 to $185.00 in a research report on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $219.22.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 479 shares of the stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the transaction, the executive vice president now owns 4,887 shares in the company, valued at approximately $964,107.36. This represents a 8.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Richard Byrd sold 459 shares of the business’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $230.00, for a total value of $105,570.00. Following the completion of the sale, the executive vice president now owns 6,952 shares in the company, valued at approximately $1,598,960. This trade represents a 6.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 4,044 shares of company stock worth $836,000 in the last 90 days. Corporate insiders own 0.36% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.